NVO: Multiplikator rega marang pendapatan Novo Nordisk Inc.

Tandha merek Novo Nordisk Inc. (NVO)

Can the hype surrounding Wegovy and Ozempic drive further growth in share prices for Novo Nordisk A/S (NVO)? The answer lies in the expansion of production facilities and a strategic focus on rare pathologies. A stable team of experts supports these ambitions, as evidenced by the shift in the P/S multiple. The current value is 2.70, reflecting the present balance between market pressure and capitalization relative to the company's revenue.

NVO (Novo Nordisk Inc.) riwayat Rasio rega marang pendapatan saka 04.07.2022 nganti 17.11.2026

Rincian metrik lan analitis perusahaan Novo Nordisk AS (NVO)

- rega saham lan target rega konsensus:
Ringkesan analitik perusahaan:Novo Nordisk AS, NVO
Sampel barang Novo Nordisk

As a global leader in diabetes therapy, Novo Nordisk A/S (NVO) is subject to the influence of cross-border trade barriers and logistical disruptions that limit access to biopharmaceutical markets. By analyzing price-to-sales dynamics, an investor assesses market capitalization relative to revenue, which allows them to filter out price volatility and determine the fair value of the business, avoiding overpaying for the asset amid geopolitical uncertainty.